FONT-SIZE Plus   Neg

Threshold Pharma's TH-302 Receives EC's Orphan Drug Designation

Threshold Pharmaceuticals, Inc. (THLD) Friday said the European Commission has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma.

Soft tissue sarcoma is an aggressive form of cancer and there is a significant unmet medical need for the condition. TH-302 was designed to selectively target hypoxic regions within tumors, which are believed not effectively treated with current therapy.

Threshold is currently conducting a pivotal Phase 3 study in soft tissue sarcoma, comparing TH-302 in combination with doxorubicin against single agent doxorubicin.

"The Orphan Drug Designation was granted as early studies of TH-302 have shown that it might be of significant benefit for patients with soft tissue sarcoma when combined with doxorubicin," said Barry Selick, Ph.D., CEO of Threshold.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Electric car maker Tesla Motors Inc. (TSLA), Wednesday reported a profit for the third quarter beating Wall Street estimates by a large margin, driven primarily by record production and deliveries. Shares of the company gained over 5 percent in extended hours after the company reaffirmed its delivery... Auvi-Q, the rival for EpiPen, will be coming back in 2017, pharmaceutical company Kaleo announced on Wednesday. Auvi-Q is a epinephrine injection used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions. Auvi-Q... Uber's self-driving technology start-up Otto has partnered with Anheuser-Busch InBev to complete the world's first shipment by a self-driving truck. Otto said in a blog post that the company and Anheuser-Busch delivered 51,744 cans of Budweiser beer from Fort Collins, through downtown Denver, to Colorado Springs.
comments powered by Disqus
Follow RTT